DeepMed Research

KEIO UNIVERSITY

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Private

Established: 1858-01-01

Employees: 1K

Market Cap: -

Website: http://www.keio.ac.jp/index-en.html

Clinical Trials

Changes in MTX-PG Concentrations During Subcutaneous MTX Therapy in Patients With Rheumatoid Arthritis(COSMOS Study)

Phase 4

Recruiting

Conditions: Rheumatoid Arthritis (RA)

Interventions: Drug: Methotrexate (MTX)

First Posted Date: 2025-04-06

Last Posted Date: 2025-04-06

Lead Sponsor: Keio University

Target Recruit Count: 100

Registration Number: NCT06913907

Locations: 🇯🇵
Keio University Hospital, Shinjuku-ku, Tokyo, Japan

Enhanced Human Sensorimotor Integration Via Self-modulation of the Somatosensory Activity

Not Applicable

Completed

Conditions: Somatosensory Evoked Potentials, and Electroencephalography

First Posted Date: 2025-02-07

Last Posted Date: 2025-02-07

Lead Sponsor: Keio University

Target Recruit Count: 39

Registration Number: NCT06814873

Locations: 🇯🇵
Keio University, Yokohama, Kanagawa, Japan

Prospective Trial to Evaluate the Safety and Efficacy to Treat Esophageal Cancer Using 5-FU, Oxaliplatin, and Docetaxel

Phase 2

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: FLOT therapy

First Posted Date: 2021-01-07

Last Posted Date: 2022-08-17

Lead Sponsor: Keio University

Target Recruit Count: 60

Registration Number: NCT04699994

Locations: 🇯🇵
Keio University Hospital, Tokyo, Japan

Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma

Phase 1

Recruiting

Conditions: Melanoma

Interventions: Drug: Pembrolizumab and Imatinib mesylate

First Posted Date: 2020-09-11

Last Posted Date: 2023-10-03

Lead Sponsor: Keio University

Target Recruit Count: 22

Registration Number: NCT04546074

Locations: 🇯🇵
Keio University Hospital, Shinjuku, Tokyo, Japan

Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and Taiwan

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Methotrexate
Drug: Adalimumab

First Posted Date: 2018-04-20

Last Posted Date: 2025-03-06

Lead Sponsor: Keio University

Target Recruit Count: 300

Registration Number: NCT03505008

Locations: 🇰🇷
Chungbuk National University Hospital, Cheongju, Korea, Republic of
🇨🇳
China Medical University Hospital, Taichung, Taiwan
🇯🇵
Keio University Hospital, Tokyo, Japan

and more 21 locations

Efficacy and Safety of Adalimumab 80 mg Every Other Week With Methotrexate

Phase 4

Conditions: Rheumatoid Arthritis

Interventions: Drug: Adalimumab

First Posted Date: 2011-01-05

Last Posted Date: 2011-06-27

Lead Sponsor: Keio University

Target Recruit Count: 40

Registration Number: NCT01270035

Locations: 🇯🇵
Saitama Medical Center, Kawagoe, Saitama, Japan
🇯🇵
Keio University Hospital, Shinanomachi, Tokyo, Japan

Confocal Microscopy and Lacrimal Gland in Sjogren's Syndrome

Conditions: Primary Sjogren's Syndrome

First Posted Date: 2009-06-15

Last Posted Date: 2009-06-15

Lead Sponsor: Keio University

Target Recruit Count: 30

Registration Number: NCT00920179

Locations: 🇯🇵
Keio University School of Medicine, Tokyo, Japan

Combination of Glinides With Premixed Insulin

Phase 4

Completed

Conditions: Type 2 Diabets Mellitus

First Posted Date: 2006-08-29

Last Posted Date: 2009-08-26

Lead Sponsor: Keio University

Target Recruit Count: 60

Registration Number: NCT00369148

Locations: 🇯🇵
Hamamatsu Red Cross Hospital, Hamamatsu, Shizuoka, Japan
🇯🇵
Kitasato Institute Hospital, Minato-ku, Tokyo, Japan
🇯🇵
Saiseikai Central Hospital, Minato-ku, Tokyo, Japan

and more 3 locations

Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: Lymphoma, Non-Hodgkin

First Posted Date: 2006-08-23

Last Posted Date: 2007-11-20

Lead Sponsor: Keio University

Target Recruit Count: 5

Registration Number: NCT00367497

Locations: 🇯🇵
Keio University School of Medicine, Tokyo, Japan

Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies

Phase 1

Completed

Conditions: Acute Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Chronic Myelogenous Leukemia
Myelodysplastic Syndrome

First Posted Date: 2005-12-29

Last Posted Date: 2012-04-06

Lead Sponsor: Keio University

Target Recruit Count: 33

Registration Number: NCT00270881

Locations: 🇯🇵
Keio University School of Medicine, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy